Jenny Feng

Jenny Feng

Auto-generated profile, based on publicly available information

Jenny Feng

Ochsner Medical Center, New Orleans, LA 70121, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2024 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
BSBarry A. Singer
Barry A. Singer
JFJenny Feng
Jenny Feng
HCHoracio Chiong-Rivero
Horacio Chiong-Rivero
Multiple sclerosis (MS) is characterized by progressive neuroinflammation and neurodegeneration from disease onset that, if left untreated, can result in the accumulation of irreversible neurological disability. Early intervention with high-efficacy therapies (HETs) is increasingly recognized as the best strategy to delay or mitigate disease progression from the earliest stages of the disease and to prevent long-term neurodegeneration. Although there is growing clinical and real-world evidence supporting early HET intervention, foregoing this strategy in favor of a traditional escalation approach prioritizing lower-efficacy disease-modifying therapies remains a common approach in clinical practice. This review explores potential health care professional- and patient-related barriers to the early use of HETs in patients with MS in the United States. Barriers can include regulatory and reimbursement restrictions; knowledge gaps and long-term safety concerns among health care professionals; and various individual, cultural, and societal factors affecting patients. Potential strategies for overcoming these barriers and encouraging early HET use are proposed.

20 June 2019 in Expert Review of Neurotherapeutics
Verified
Journal Article
Closed access
LBLaura E. Baldassari
Laura E. Baldassari
JFJenny Feng
Jenny Feng
BCBenjamin L.L. Clayton
Benjamin L.L. Clayton
SOSe-Hong Oh
Se-Hong Oh
KSKen Sakaie
Ken Sakaie
JCJeffrey A. Cohen
Jeffrey A. Cohen
Introduction: Approved disease modifying therapies for multiple sclerosis (MS) lessen inflammatory disease activity that causes relapses and MRI lesions. However, chronic inflammation and demyelination lead to axonal degeneration and neuronal loss, for which there currently is no effective treatment. There has been increasing interest in developing repair-promoting strategies, but there are important unanswered questions regarding the mechanisms and appropriate methods to evaluate these treatments. Areas covered: The rationale for remyelinating agents in MS is discussed, with an overview of both myelin physiology and endogenous repair mechanisms. This is followed by a discussion of identification and development of potential remyelinating drugs. Potential biomarkers of remyelination are reviewed, including considerations regarding measuring remyelination in clinical trials. Information and data were obtained from a search of recent literature through PubMed. Peer-reviewed original articles and review articles were included. Expert opinion: There are several obstacles to translation of potential remyelinating agents to clinical trials, particularly uncertainty regarding the most appropriate study population and method to monitor remyelination. Refinements in clinical trial design and outcome measurement, potentially via advanced imaging techniques, are needed to optimize detection of repair in patients with MS.

1 November 2019 in Pediatric Health, Medicine and Therapeutics
Verified
Journal Article
Open access
PDF file
JFJenny Feng
Jenny Feng
Mary RenselMary Rensel
Mary Rensel
Pediatric-onset multiple sclerosis (POMS) is an immune-mediated, demyelinating, neurodegenerative disease that accounts for 3–5% of all multiple sclerosis (MS) cases. Although evidence suggests that it has similar risk factors and disease pathophysiology as adult-onset MS (AOMS), there are distinctive features in disease characteristics and patient demographics of POMS that require unique therapeutic development and treatment considerations. Gilenya® (Novartis International AG, Basel, Switzerland) (fingolimod) is a sphingosine-1-phosphate (S1P) receptor modulator that prevents lymphocytic outflow from peripheral lymph nodes. It has demonstrated efficacy in AOMS. In POMS, there have been three observational studies and one pivotal clinical trial evaluating the efficacy, safety, and tolerability of fingolimod. Currently, fingolimod is the only Food and Drug Administration and European Medicines Agency approved disease-modifying therapy to treat POMS. This review will critically evaluate the available evidence of fingolimod in the treatment of POMS in detail, as well as discussing its treatment implications.

1 October 2019 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
PDF file
LBLaura E Baldassari
Laura E Baldassari
SPSarah M. Planchon
Sarah M. Planchon
RBRobert A Bermel
Robert A Bermel
KNKunio Nakamura
Kunio Nakamura
EFElizabeth Fisher
Elizabeth Fisher
JCJeffrey A Cohen
Jeffrey A Cohen
Serum neurofilament light chain concentration is a proposed biomarker of axonal injury in multiple sclerosis. Mesenchymal stem cells have anti-inflammatory and repair-promoting activities, making them of interest for potential multiple sclerosis treatment. The purpose of this study was to assess correlation of serum neurofilament light chain concentration and measures of multiple sclerosis disease activity/severity, longitudinal stability of serum neurofilament light chain concentration, and treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration. Twenty-four multiple sclerosis patients underwent intravenous infusion of autologous mesenchymal stem cells. Clinical assessments, serum collection, and brain magnetic resonance imaging were performed at months –1, 0 (transplant), 1, 3, and 6. Matched control serum was collected once (n = 10). Serum neurofilament light chain concentration was measured by single-molecule array. Serum neurofilament light chain concentration correlations with disease measures were analyzed by Spearman correlations and linear mixed effect models. Pre-post transplant serum neurofilament light chain concentration was compared by Wilcoxon signed rank testing. There were significant (p<0.01) correlations between serum neurofilament light chain concentration and gadolinium-enhancing lesion number (rho = 0.55) and volume (rho = 0.65), and new/enlarging T2 lesions (rho = 0.65). Patients without disease activity had lower fluctuation in serum neurofilament light chain concentration (p = 0.01). Mean pre- versus post-treatment serum neurofilament light chain concentration values were not significantly different. Serum neurofilament light chain concentration correlated with magnetic resonance imaging measures of disease activity cross sectionally and longitudinally, and was stable in patients without disease activity. There was no clear treatment effect of mesenchymal stem cell transplantation on serum neurofilament light chain concentration.

1 April 2019 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
PDF file
JFJenny Feng
Jenny Feng
EOErik Offerman
Erik Offerman
JLJian Lin
Jian Lin
EFElizabeth Fisher
Elizabeth Fisher
SPSarah M. Planchon
Sarah M. Planchon
DODaniel Ontaneda
Daniel Ontaneda
Background: Mesenchymal stem cells (MSC) have immunomodulatory and neuro-protective properties and are being studied for treatment of multiple sclerosis (MS). Tractography-based diffusion tensor imaging (DTI), cortical thickness (Cth) and T2 lesion volume (T2LV) can provide insight into treatment effects. Objective: The objective of this study was to analyse the effects of MSC transplantation in MS on exploratory MRI measures. Methods: MRIs were obtained from 24 MS patients from a phase 1 open-label study of autologous MSC transplantation. DTI metrics were obtained in lesions and normal-appearing white matter motor tracts (NAWM). T2LV and Cth were derived. Longitudinal evolution of MRI outcomes were modelled using linear mixed effects. Pearson’s correlation was calculated between MRI and clinical measures. Results: Lesional radial diffusivity (RD) and axial diffusivity (AD) decreased pre-transplant and showed no changes post-transplant. There were mixed trends in NAWM RD and AD pre/post-transplant. Transplantation stabilized T2LV growth. NAWM RD and AD correlated with Cth, T2LV and with leg and arm function but not with cognition. Lesional DTI demonstrated similar but less robust correlations. Conclusions: Microstructural tissue integrity is altered in MS. DTI changes pre-transplant may be influenced by concomitant lesion accrual. Contributor to DTI stabilization post-transplant is multifactorial. DTI of major motor tracts correlated well with clinical measures, highlighting its sensitivity to clinically meaningful changes.

1 July 2019 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
PDF file
LBLaura E Baldassari
Laura E Baldassari
JFJenny Feng
Jenny Feng
GMGabrielle Macaron
Gabrielle Macaron
SPSarah M. Planchon
Sarah M. Planchon
EAEbtesam Alshehri
Ebtesam Alshehri
MWMary A Willis
Mary A Willis
Tuberculosis screening is recommended in multiple sclerosis patients starting certain disease-modifying therapies. Disease-modifying therapies may affect interferon-gamma release assay results. To determine the effects of multiple sclerosis disease-modifying therapies on interferon-gamma release assay results. Indeterminate interferon-gamma release assay results among multiple sclerosis patients were compared across disease-modifying therapies by Fisher’s exact test. Logistic regression evaluated the effects of lymphopenia on interferon-gamma release assay results. A total of 1058 patients underwent interferon-gamma release assay: 2.0% (21) positive, 6.1% (65) indeterminate, with 59.4% (628) on disease-modifying therapies. Results were significantly different across disease-modifying therapies (P = 0.002). Absolute lymphocyte count less than 0.5 k/μL had 9.39 times (95% confidence interval 5.2–17.0) increased odds of indeterminate interferon-gamma release assay results. Disease-modifying therapies affecting lymphocytes had a higher risk of indeterminate interferon-gamma release assay results.